To include your compound in the COVID-19 Resource Center, submit it here.

Breakthrough designation for Global Blood's sickle cell therapy

Global Blood Therapeutics Inc. (NASDAQ:GBT) said FDA granted voxelotor (formerly GBT440) breakthrough therapy designation to treat sickle

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE